MS MORGAN STANLEY
Price Chart
Executive Summary
The Ninth Circuit partially reversed a district court ruling in an ERISA benefits dispute against Morgan Stanley's medical plan. The appellate court found that the plan administrator (Cigna) abused its discretion by relying on an internal policy rather than the governing plan document, and that the district court improperly supplied post-hoc rationalization. The case was remanded for reevaluation of the claim under the correct plan definition. This is a narrow, non-precedential ruling with no material financial exposure to Morgan Stanley.
Court Ruling Details
Actionable Insight
This ruling has no material financial impact on Morgan Stanley. It is a narrow ERISA procedural dispute over a single employee's medical claim, with no damages, no injunction, and no precedent value. No trading action warranted.
Key Facts
- Ninth Circuit affirmed no conflict of interest by plan administrator Cigna
- Ninth Circuit reversed the denial of benefits, finding Cigna abused its discretion by relying on internal MCP policy instead of the governing SPD
- District court's post-hoc rationalization was improper; case remanded for reevaluation under SPD definition
- Ruling is non-precedential (NOT FOR PUBLICATION) and concerns a single employee's medical benefit claim
- No damages awarded; no financial exposure to Morgan Stanley beyond potential administrative costs of reevaluation
Financial Impact
No damages awarded; the only potential cost is administrative reevaluation of a single benefits claim, which is immaterial to a $344B market cap company
Risk Factors
- No material risk identified — ruling is non-precedential and involves trivial exposure
Market Snapshot
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-17mhuy9s-MS |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 6, 2026
8d ago
|
ANALYST-UPGRADE
| $168.36 $189.21 | ▲ +12.38% | ▲ +2.60% | $214.04 (+27.13%) |
|
Jun 5, 2026
10d ago
|
Court Ruling
| $218.17 awaiting T+20 | awaiting T+20 | — | $214.04 (−1.89%) |
|
May 31, 2026
14d ago
|
ANALYST-UPGRADE
| $162.76 $179.44 | ▲ +10.25% | ▲ +7.39% | $214.04 (+31.51%) |
|
May 7, 2026
5w ago
|
ANALYST-UPGRADE
| $168.36 $189.21 | ▲ +12.38% | ▲ +2.60% | $214.04 (+27.13%) |
|
May 1, 2026
6w ago
|
ANALYST-UPGRADE
| $162.76 $179.44 | ▲ +10.25% | ▲ +7.39% | $214.04 (+31.51%) |
|
Apr 16, 2026
8w ago
|
Insider Cluster
| $186.67 $193.83 | ▲ +3.84% | ▼ −1.98% | $214.04 (+14.66%) |
|
Apr 16, 2026
8w ago
|
Insider Cluster
| $186.67 $193.83 | ▲ +3.84% | ▼ −1.98% | $214.04 (+14.66%) |
|
Apr 15, 2026
8w ago
|
8-K
| $20.63 $20.43 | ▼ −0.95% | ▼ −7.00% | $214.04 (+937.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access